Vanguard Group’s Strongbridge Biopharma plc. SBBP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-2,200,172
| Closed | -$4.49M | – | 4729 |
|
|
2021
Q3 | $4.49M | Hold |
2,200,172
| – | – | ﹤0.01% | 3728 |
|
|
2021
Q2 | $6.53M | Sell |
2,200,172
-114,043
| -5% | -$301K | ﹤0.01% | 3445 |
|
|
2021
Q1 | $6.39M | Buy |
2,314,215
+260,639
| +13% | +$786K | ﹤0.01% | 3396 |
|
|
2020
Q4 | $4.99M | Buy |
2,053,576
+170,385
| +9% | +$410K | ﹤0.01% | 3354 |
|
|
2020
Q3 | $3.96M | Buy |
1,883,191
+11,222
| +0.6% | +$37.8K | ﹤0.01% | 3270 |
|
|
2020
Q2 | $7.08M | Buy |
1,871,969
+64,959
| +4% | +$195K | ﹤0.01% | 2925 |
|
|
2020
Q1 | $3.42M | Buy |
1,807,010
+355,876
| +25% | +$925K | ﹤0.01% | 3133 |
|
|
2019
Q4 | $3.03M | Buy |
1,451,134
+991,273
| +216% | +$1.9M | ﹤0.01% | 3332 |
|
|
2019
Q3 | $1.1M | Buy |
459,861
+377,747
| +460% | +$1.01M | ﹤0.01% | 3628 |
|
|
2019
Q2 | $257K | Buy |
+82,114
| New | +$302K | ﹤0.01% | 3934 |
|
|
2018
Q2 | – | Sell |
-89,978
| Closed | -$796K | – | 4141 |
|
|
2018
Q1 | $796K | Buy |
89,978
+13,394
| +17% | +$100K | ﹤0.01% | 3700 |
|
|
2017
Q4 | $555K | Buy |
76,584
+10,837
| +16% | +$67.7K | ﹤0.01% | 3720 |
|
|
2017
Q3 | $454K | Sell |
65,747
-631
| -1% | -$4.35K | ﹤0.01% | 3772 |
|
|
2017
Q2 | $474K | Buy |
+66,378
| New | +$307K | ﹤0.01% | 3738 |
|
Vanguard Group's SBBP Position: Q4 2021 in Review
Vanguard Group sold out of Strongbridge Biopharma plc. (SBBP) in Q4 2021, closing a stake of 2,200,172 shares — an estimated $4.49M sold.
Vanguard Group first reported a position in SBBP in Q2 2017 and held it in 14 quarters. The position peaked at $7.08M in Q2 2020. 0 funds tracked by Wall St. Rank hold SBBP as of Q4 2021.
- Vanguard Group reported no remaining Strongbridge Biopharma plc. position as of Q4 2021 after selling out during the quarter.
- Vanguard Group sold 2,200,172 Strongbridge Biopharma plc. shares in Q4 2021, an estimated $4.49M.
- Vanguard Group first reported a position in Strongbridge Biopharma plc. in Q2 2017 and held it in 14 quarters.
- Vanguard Group's Strongbridge Biopharma plc. position peaked at $7.08M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q4 2021.
Based on Vanguard Group's 13F filing for Q4 2021, filed 14 Feb 2022.